Product Information
DOXEPIN 25 MG CAPSULE is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1415 per EA under NDC 64980059501. Its NADAC has been published 132 times since Mar 27, 2024.
FDA first approved this application on Aug 21, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980059501
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXEPIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA217975FDA Approved
8/21/2023
TE Code
AB
On Market Since
12/25/2023
Pharmacological Classes
Price Statistics
The NADAC for DOXEPIN 25 MG CAPSULE has been published 132 times since Mar 27, 2024, and over the history we have for it it has declined 28.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1415 per EA |
|---|---|
| All-time high | $0.1975 (Apr 10, 2024) |
| All-time low | $0.1216 (Nov 20, 2024) |
| 52-week high | $0.1415 |
| 52-week low | $0.1242 |
| Median price | $0.1310 |
| Average price | $0.1351 |
| Largest weekly change | -28.2% (Apr 17, 2024) |
| Weeks tracked | 132 |
| Tracking since | Mar 27, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Doxepin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXEPIN 25 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DOXEPIN 25 MG CAPSULE, manufactured by Rising Pharma Holdings Inc., is $0.1415 per EA (NDC 64980059501), effective Sep 30, 2026.
How has the price of DOXEPIN 25 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DOXEPIN 25 MG CAPSULE has declined 28.4%. It has been tracked across 132 weekly CMS publications since Mar 27, 2024.
What are the highest and lowest recorded NADAC prices for DOXEPIN 25 MG CAPSULE?
Since Mar 27, 2024, the NADAC for DOXEPIN 25 MG CAPSULE has ranged from a low of $0.1216 (Nov 20, 2024) to a high of $0.1975 (Apr 10, 2024), with a median of $0.1310 per EA.
Are there cheaper alternatives to DOXEPIN 25 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as DOXEPIN 25 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures DOXEPIN 25 MG CAPSULE?
DOXEPIN 25 MG CAPSULE (NDC 64980059501) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.